10 Best Breakout Stocks to Invest In

7. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Share Price as of November 14: $13.62

200-Day Simple Moving Average: $12.36

Relative Volume: 2.89

Number of Hedge Fund Holders: 28

Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) is one of the best breakout stocks to invest in. On November 11, analysts at Citizens lowered their price target of the stock to $28 from $29 while reiterating a Market Perform rating. Despite the cut, the price target remains well above the current trading range, indicating significant upside potential.

The research firm remains confident about Kalvista Pharmaceuticals’ prospects, given the successful launch of EKTERLY, the only oral on-demand therapy to treat hereditary angioedema (HAE) attacks. Oral treatment is attracting strong demand and rapid adoption among physicians and individuals with HAE. The therapy has already attracted 937 start forms covering about 8% of the people diagnosed with HAE in the US. The start form translates to about $31 million in potential revenue.

The company has already launched EKTERLY in Germany, with approval in Australia, bringing the total number of regulatory approvals to five.

“We continue to see encouraging trends, with both new patient starts and repeat prescriptions increasing consistently, reflecting sustained uptake and confidence in the clinical value of EKTERLY as the first and only oral on-demand treatment for hereditary angioedema,” said Ben Palleiko, CEO of KalVista

During the third quarter, Kalvista achieved $13.7 million in net product revenue. It exited the quarter with $309.2 million in cash and cash equivalents and expects projected EKTERLY revenue to propel it to profitability.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a biopharmaceutical company focused on developing and commercializing oral therapies for rare diseases, primarily hereditary angioedema (HAE). They develop small-molecule inhibitors that target the plasma kallikrein enzyme in the kallikrein-kinin system, which is a key driver of HAE attacks.